Home / Companies / News / Sanofi-GSK Covid-19 vaccine gets nod to start phase-3 trials in India

Sanofi-GSK Covid-19 vaccine gets nod to start phase-3 trials in India

India part of 35,000 volunteer global efficacy trial

Sanofi and Glaxo plan to move on to a final-stage trial involving more than 35,000 participants from a range of countries.

Premium

India will be part of the global randomised, double-blind phase-3 study to assess the safety, efficacy and immunogenicity of their vaccine would include more than 35,000 adult volunteers across US, Asia, Africa and Latin America.

Sohini Das Mumbai

4 min read Last Updated : Jul 08 2021 | 11:51 PM IST

French pharmaceutical giant Sanofi and its British partner GlaxoSmithKline (GSK) plc have received approval from the Drugs Controller General of India (DCGI) to conduct a part of the global Phase 3 efficacy trial of their jointly developed Covid vaccine in India.

The approval by DCGI marks the first such global trial for a foreign Covid vaccine to be conducted in India — the enrolments are expected to begin soon.

India will be part of the global randomised, double-blind Phase 3 study to assess the safety, efficacy, and immunogenicity of their vaccine. This will include more than 35,000 adult volunteers across the US,

Topics : Coronavirus Coronavirus Vaccine Sanofi GSK

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in